Cancer Options Blog

This blog is a way of sharing, supporting and educating anyone dealing with a cancer-related illness about the options and treatments they have at their disposal.

You're browsing: Home » Blog » Cancer Options, Featured » Blog article: ASTRO’s 49th annual meeting of radiation oncology

ASTRO’s 49th annual meeting of radiation oncology

This Article was Written January 22nd, 2008

Powered by Gregarious (39)

ProxcelanTM (Cesium-131) is the newest advancement in permanent brachytherapy seed implants for prostate cancerLOS ANGELES, CA - Several newly released scientific findings focusing on various aspects of ProxcelanTM (Cesium-131) seeds’ effectiveness in the treatment of prostate cancer–supporting and broadening the growing body of evidence on the newest medical isotope being used in permanent seed therapy.

The findings - which include one in a new area of investigation, and four in continuing areas of investigation - reinforce preceding published results about the success of Cesium-131. These studies add over 400 patients to the overall number of subjects being observed in Cesium-131 clinical studies.

The results by leading cancer researchers were presented at the 49th ASTRO Annual Meeting, held in Los Angeles, October 28-November 1, 2007. ASTRO is the largest radiation oncology organization of its kind, with over 9,000 members who include radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists, and biologists.

Proxcelan (www.proxcelan.com) is the brand name of the medical isotope Cesium-131 used in brachytherapy seed treatment, specifically for prostate cancer. It is a proprietary product of IsoRay MedicalTM - a wholly-owned subsidiary of a public company, IsoRay, Inc. (”IsoRay”) (AMEX Symbol: ISR), based in Richland, WA. Proxcelan is currently available in over 50 medical centers across the U.S.

“The findings presented at ASTRO further support and confirm earlier results regarding Proxcelan’s excellent dosimetric properties and applicability for prostate cancer,” said IsoRay Chairman and CEO Roger Girard. “From a patient’s standpoint, this underscores Proxcelan’s advantages–targeting cancer cells while allowing the patient to resume normal activities quickly. Quality of life issues are increasingly important to patients as well as physicians dealing with follow-up care.”

A key finding of the latest study entitled, Is Cesium-131 or Iodine-125 or Palladium-103 the “Ideal” Isotope for Prostate Boost Brachytherapy? - A Dosimetric Viewpoint, is that Cesium-131 seeds yielded “homogeneous” dose distributions within the prostate while providing desired dose coverage and acceptable normal tissue doses compared to Iodine-125 or Palladium-103 seed implants. The lead researcher who conducted the 15-patient study is W. Choi; research institutions involved were the Montefiore Medical Center, the Albert Einstein College of Medicine, Bronx, New York, NY and The Haakon Ragde Foundation for Advanced Cancer Studies, Seattle, WA.

Powered by Gregarious (39)

Share This Post - instructions included

One Response

  1. Floyd Kolmer Says:
    January 31st, 2008 at 9:04 pm

    I am a recent prostate cancer survivor and was treated with the Proxcelan Cesium 131 seed and my experience was incredible. Literally no side effects. My hospital stay was only a few hours and back to my regular activities the next day. No real discomfort and my PSA dropped by 75% on my first check up. I strongly recommend this product and strongly recommend seed implants

PLEASE post a comment below

  • Categories

  • Subscribe

    All posts by all authors Google Reader or Homepage Subscribe Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online Add to My AOL Subscribe in Rojo Add to Technorati Favorites!
    Business Blogs - BlogCatalog Blog Directory

    Enter your email address:

    Comments (RSS)

  • Random Posts & Pages

    Early Screening Reduces Disparities For Prostate Cancer

  • Early Screening Reduces Disparities For Prostate Cancer Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according

    • All About Robot-Assisted Prostate Surgery

  • What Should You Know About FascinatingTreatment Option?By Matthew Schmitz, M.D., About.com GuideCreated: November 19, 2009About.com Health's Disease and Condition content is reviewed by the Medical Review BoardRobot-assisted prostate surgery is a relatively new treatment option for prostate cancer. So what do you need to know about this fascinating surgical option?How Does Robot-Assisted Prostate

    • MRI combo spots prostate cancer treatment failure

  • Two imaging modalities used in combination -- dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI)-MRI -- can accurately spot residual or recurrent prostate cancer in patients treated with a fairly new treatment called high-intensity focused ultrasonic ablation, a new study shows.Together these two imaging modalities are better than

    • Are Prostate Needle Biopsies Predictive Of The Laterality Of Significant Cancer And Positive Surgical Margins?

  • Are Prostate Needle Biopsies Predictive Of The Laterality Of Significant Cancer And Positive Surgical Margins? UroToday.com - In the online edition of the British Journal of Urology International, Dr. Rodrigo Frota presents the single surgeon laparoscopic radical prostatectomy (LRP) experience of Dr. Inderbir Gill. The study is a retrospective review with the intent

    • Strikeout prostate cancer

  •  About one in six men is diagnosed with prostate cancer. If it's caught early, the cancer is almost 100-percent curable, but if it goes undetected, it can be deadly. So now a new campaign is raising money and getting guys attention . . . with America's favorite pasttime. As major league

    • ASTRO: Brachytherapy Called Prostate Cancer Option for Younger Men

  • By Michael Smith, Senior Staff Writer, MedPage Today Published: October 31, 2007 Reviewed by Zalman S. Agus, MD; Emeritus Professor at the University of Pennsylvania School of Medicine. LOS ANGELES, Oct. 31 -- Younger men with prostate cancer benefit just as much from brachytherapy as older men, a researcher said here.Younger age is often thought

    • De Niro Beats Prostate Cancer Suit

  • A Los Angeles judge on Tuesday granted the actor's request to toss a lawsuit filed against him by an insurance company that claimed De Niro intentionally withheld that he had prostate cancer before the insurer signed on to cover one of his films. Fireman's Fund Insurance Co. insured the production of

    • Molecular Fingerprints Point The Way To Earlier Cancer Diagnosis And More Targeted Treatment

  • Molecular Fingerprints Point The Way To  Earlier Cancer Diagnosis And More Targeted Treatment ScienceDaily (Mar. 23, 2009) — Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.   You've likely heard about metabolites; your physician probably screens for some known ones

    • Privacy Policy

  • IsoRay Medical, Inc. Privacy Policy IsoRay Medical, Inc. is committed to protecting your privacy.  This Privacy Policy (this "Policy") describes certain policies of IsoRay Medical, Inc. and its affiliates (“IsoRay,” “we” or “us”) with respect to its collection and use of certain information.  This Policy applies to personal information collected by us

    • Unproven cancer therapy lures U.S. men to Mexico

  • Article from The New York Times By Stephanie Saul PUERTO VALLARTA, Mexico - Some weekends, more than a dozen American men wait at beachfront hotels, eager for their turns in the treatment room at a small private hospital here. They are medical tourists with prostate cancer. And they are queued up for the


  •  

    July 2010
    M T W T F S S
    « Jan    
     1234
    567891011
    12131415161718
    19202122232425
    262728293031  
images